XML 20 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Cash flows from operating activities:              
Net loss $ (3,854,310) $ (3,438,337) $ (1,442,792) $ (892,049) $ (11,279,158) $ (7,365,005)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Acquired in-process research and development charge 0   0   500,000 3,087,832  
Fair value of warrants for services provided         0 371,895  
Share-based compensation expense         732,803 306,699  
Depreciation and amortization expense         6,074 0  
Non-cash interest expense         0 64,555  
Change in fair value of convertible promissory notes 0   0   0 (9,317)  
Reduction in the carrying amount of operating lease right-of-use asset         56,736 0  
Gain on extinguishment of debt         0 (125,577)  
Changes in operating assets and liabilities:              
Prepaid expenses and other current assets         (891,912) (9,707)  
Other assets         (39,313) 0  
Accounts payable         (229,228) (179,199)  
Accrued expenses and other current liabilities         1,576,728 20,021  
Operating lease liability         (52,291) 0  
Cash used in operating activities         (9,619,561) (3,837,803)  
Cash flows from investing activities:              
Acquired in-process research and development         (500,000) (250,000)  
Purchase of property and equipment         (36,836) 0  
Cash used in investing activities         (536,836) (250,000)  
Cash flows from financing activities:              
Proceeds from the sale of Series A preferred stock, net         0 4,982,835  
Cash (used in) provided by financing activities         (102,071) 4,165,918  
Net (decrease) increase in cash, cash equivalents and restricted cash         (10,258,468) 78,115  
Cash, cash equivalents and restricted cash at beginning of period   $ 49,685,586   $ 341,037 49,685,586 341,037 $ 341,037
Cash, cash equivalents and restricted cash at end of period $ 39,427,118   $ 419,152   39,427,118 419,152 $ 49,685,586
Supplemental disclosure of non-cash activities:              
Conversion of convertible promissory notes, including accrued interest, to Series A preferred stock         0 5,866,290  
Series A preferred stock issued for acquired in-process research and development         0 2,837,832  
Deferred offering costs in accounts payable and accrued expenses         0 1,004,856  
Right-of-use asset obtained in exchange for lease obligation         130,488 0  
Change in fair value of redeemable common stock to redemption value         0 53,330  
Private Placement              
Cash flows from financing activities:              
Payments for offering costs related to the private placement sale of common stock         (102,071) 0  
IPO              
Cash flows from financing activities:              
Payments for offering costs related to the private placement sale of common stock         0 (816,917)  
Warrants issued in conjunction with series A preferred stock              
Supplemental disclosure of non-cash activities:              
Issuance of warrants in conjunction with Series A preferred stock         0 309,390  
Issuance of warrants for services provided         0 309,390  
Issued for services              
Supplemental disclosure of non-cash activities:              
Issuance of warrants in conjunction with Series A preferred stock         345,530 0  
Issuance of warrants for services provided         $ 345,530 $ 0